Corona Remedies Ltd

Stage 2 · Advancing · week 2Setup 2.9 WatchEven +0.8

As of 16 Oct 2026, Corona Remedies is in Stage 2 — advancing, the uptrend phase, in week 2 (since 6 Oct 2026). It closed at ₹2,004, above its 200-day average. In Health Care, 40.0% of stocks are in Stage 2.

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. More about the company

₹2,003.9
-2.00% today
Market Neutral — FadingHealth Care 40.0% in Stage 2-7.4 pts / 20dPharmaceuticals 49.6%-2.5 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

2.9 Watch

Momentum

Steady

Edge

Even +0.8

Setup-score rank among Stage 2 peers: #56 of 59 in Pharmaceuticals · #66 of 70 in Health Care

Is CORONA early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
—
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 2
1w13w26w
Week 2 — fresh breakout, verify structure
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
11.9%
200 DMA: ₹1,791.6
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
3.04x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↓
MA20 rolling over · -3.0% vs MA50 +0.0%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-6.5%
3M
-2.8%
6M
+27.2%
YTD
+47.9%
1Y
—
Sector
Health Care
↓ Peaking
Stage 2%
40.0%
20d Δ
-7.4pp
1M return
-3.8%
3M return
-1.0%
Sector Stage-2 % · last 20 days
Industry
Pharmaceuticals
↓ Peaking
Stage 2%
49.6%
20d Δ
-2.5pp
1M return
-2.3%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Stage Cycle Timeline2025-12-15 → 2026-10-16
S? 42w
2025-12-152026-10-16
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 42w → S2 2w current
Total tracked: 44 weeks across 2 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-10-06
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-16S2
Wk 2 · Vol 3.04x
2026-10-15S2
Wk 2 · Vol 0.17x
2026-10-14S2
Wk 2 · Vol 0.22x
2026-10-13S2
Wk 2 · Vol 0.51x
2026-10-12S2
Wk 1 · Vol 0.20x
2026-10-09S2
Wk 1 · Vol 0.30x
2026-10-08S2
Wk 1 · Vol 0.34x
2026-10-07S2
Wk 1 · Vol 0.17x
2026-10-06S2
Wk 1 · Vol 0.57x
2026-10-05S—
Wk 41 · Vol 0.31x
2026-10-01S—
Wk 41 · Vol 0.57x
2026-09-30S—
Wk 41 · Vol 0.52x
Sector Peers — Stage 2All →
BAFNAPH
wk 19 · 0.0% from hi
8.6
KILITCH
wk 3 · -11.6% from hi
8.4
LAURUSLABS
wk 26 · -0.4% from hi
7.8
KOPRAN
wk 20 · -6.8% from hi
7.4
ZIMLAB
wk 23 · -5.2% from hi
6.9
Moving averages & range
50 DMA
₹2,101.3
200 DMA
₹1,791.6
52W High
—
52W Low
—
5D Low
₹2,003.9
Resistance levels (recent highs)
20d High
₹2,210
60d High
₹2,236.1
120d High
₹2,236.1
250d High
—
Next resistance
+10.3%
to 20d High
Ask the Market AI about CORONAAsk →
P/E (TTM)
55.5
Forward 31.5
Earnings Growth (YoY)
+43.6%
Revenue +20.2%
ROE
+27.4%
Profit margin +13.2%
Dividend Yield
0.59%
P/B 13.7
About this companyHealth Care· Pharmaceuticals

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women's healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-16. Past data patterns are not indicative of future results. This page is a data analytics tool only.